Short Interest in Traws Pharma, Inc. (NASDAQ:TRAW) Declines By 36.2%

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 172,300 shares, a decrease of 36.2% from the February 13th total of 270,200 shares. Based on an average daily trading volume, of 570,800 shares, the days-to-cover ratio is presently 0.3 days. Approximately 6.5% of the shares of the stock are sold short.

Institutional Trading of Traws Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TRAW. Millennium Management LLC purchased a new stake in Traws Pharma in the 4th quarter worth about $89,000. Renaissance Technologies LLC purchased a new stake in Traws Pharma in the 4th quarter worth about $89,000. Geode Capital Management LLC purchased a new stake in Traws Pharma in the 4th quarter worth about $185,000. Boothbay Fund Management LLC purchased a new position in shares of Traws Pharma during the fourth quarter worth approximately $252,000. Finally, Vestal Point Capital LP purchased a new position in shares of Traws Pharma during the fourth quarter worth approximately $666,000. 7.95% of the stock is owned by hedge funds and other institutional investors.

Traws Pharma Price Performance

Shares of NASDAQ TRAW opened at $2.74 on Monday. The firm’s 50-day simple moving average is $5.72. The stock has a market cap of $10.00 million, a PE ratio of -0.02 and a beta of 1.42. Traws Pharma has a 12-month low of $2.02 and a 12-month high of $24.75.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.